PGD for Aneuploidy Screening (PGD-AS)
Preimplantation genetic testing is currently the only way to
determine if the egg or embryo contains an abnormal number
of chromosomes prior to pregnancy. PGD has been used for the
screening of embryos for common aneuploidies in couples
undergoing IVF procedures for infertility with a history of
recurrent pregnancy loss, repeated IVF failures and/or
advanced maternal age (women age 35 and older).This may not
only contribute to the prevention of the birth of children
with common chromosomal abnormalities but also to the
efficiency of IVF.
When PGD is performed for any of these indications, it has
been referred to by the ESHRE Consortium as PGD-AS, or
preimplantation genetic diagnosis for aneuploidy screening.
It is also referred to as preimplantation genetic screening
This is PGD for the detection of sporadic chromosomal
abnormalities with the goal of increasing reproductive
success (as well as prevention of the birth of affected
offspring). Essentially, this use of PGD is a screening
procedure to detect those aneuploidies most commonly
observed after birth or in miscarriages (involving detection
of chromosomes X, Y, 13, 16, 18, 21, and 22).
Our Centre is able to test for a total of 11 chromosomes (8,
9, 13, 15, 16, 17, 18, 21, 22, X, Y).